Fibromyalgia: Nosography and therapeutic perspectives

Pain Practice

Volumn 8, Issue 3, 2008, Pages 190-201

  Coaccioli, Stefano ^a   Varrassi, Giustino ^b   Sabatini, Chiara ^a   Marinangeli, Franco ^b   Giuliani, Marco ^a   Puxeddu, Adolfo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Fibromyalgia; Multimodal management; Serotonergic mechanisms

Indexed keywords

AMITRIPTYLINE; BOTULINUM TOXIN; BUPRENORPHINE; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; CORTICOSTEROID; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; GABAPENTIN; IBUPROFEN; LIDOCAINE; MILNACIPRAN; MIRTAZAPINE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OPIATE DERIVATIVE; OXYBATE SODIUM; PHENYTOIN; PLACEBO; PRAMIPEXOLE; PREGABALIN; STEROID; TRIAMCINOLONE; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON; UNINDEXED DRUG; VENLAFAXINE;

ACUPUNCTURE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DISEASE SEVERITY; DROWSINESS; DRUG POTENTIATION; DRUG TREATMENT FAILURE; EPIDEMIOLOGICAL DATA; FIBROMYALGIA; HEALTH CARE COST; HUMAN; LOW LEVEL LASER THERAPY; METABOLIC DISORDER; MORBIDITY; NAUSEA; NEUROENDOCRINE DISEASE; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; PATHOGENESIS; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYMPATHETIC TONE; TRANSCRANIAL MAGNETIC STIMULATION; TRANSCUTANEOUS NERVE STIMULATION; WEIGHT GAIN;

ANALGESICS; COMBINED MODALITY THERAPY; COMORBIDITY; DOPAMINE; FATIGUE; FEMALE; FIBROMYALGIA; HEADACHE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; MYOFASCIAL PAIN SYNDROMES; NEUROSECRETORY SYSTEMS; NOCICEPTORS; PAIN; RHEUMATIC DISEASES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS, INTRINSIC; TERMINOLOGY AS TOPIC;

EID: 43449092211     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2008.00188.x     Document Type: Article

References (90)

1. Gowers WR. A lesson on lumbago. its lessons and analogues. BMJ. 1904; 1: 117-121.
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia. Report Multicenter Criteria Committee Arthritis Rheum. 1990; 33: 160-172.
3. Mease P. Fibromyalgia syndrome. review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol. 2005; 32: 6-21.
4. Aron LA, Buchwald D. Chronic diffuse musculoskeletal pain fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol. 2003; 17: 563-574.
5. Buskila D. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol. 2001; 13: 117-127.
6. Edinger JD, Wohlgemuth WK, Krystal AD, Rice JR. Behavioural insomnia therapy for fibromyalgia patients: A randomized clinical trial. Arch Intern Med. 2005; 165: 2527-2535.
7. Roizenblatt S, Fregni F, Gimenez R, etal. Site-specific effects of transcranial direct current stimulation on sleep and pain in fibromyalgia: A randomized, sham-controlled study. Pain Prac. 2007; 7: 297-306.
8. Fitzcharles MA, Esdaile JM. The overdiagnosis of fibromyalgia syndrome. Am J Med. 1997; 103: 44-50.
9. Daoud KF, Baarkhuizen A. Rheumatic mimics and selected triggers of fibromyalgia. Curr Pain Headache Rep. 2002; 6: 284-288.
10. Van HB, Egle UT. Fibromyalgia: A stress disorder? Piecing the biopsychosocial puzzle together. Psychother Psychosom. 2004; 73: 267-271.
11. Menninger H. Other pain syndromes to be differentiated from fibromyalgia. Z Rheumatol. 1998; 57(Suppl. 2): 56-60.
12. Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum. 1994; 37: 1181-1188.
13. Bonafede RP, Downey DC, Bennett RM. An association of fibromyalgia with primary Sjogren's syndrome. a prospective study of 72 patients. J Rheumatol. 1995; 22: 133-136.
14. Clark S, Tindall E, Bennett RM. A double-blind crossover trial of prednisone vs placebo in the treatment of fibrositis. J Rheumatol. 1985; 12: 980-983.
15. Goldenberg DL, Simms RW, Geiger A, Komaroff AL. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum. 1990; 33: 381-387.
16. Goulding C, O'Connell P, Murray FE. Prevalence of fibromyalgia, anxiety, and depression in chronic hepatitis C virus infection: Relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol. 2001; 13: 507-511.
17. Hsu VM, Patella SJ, Sigal LH. 'Chronic Lyme disease'as the incorrect diagnosis in patients with fibromyalgia. Arthritis Rheum. 1993; 35: 1493-1500.
18. Sergi M, Rizzi M, Braghiroli A, et al. Periodic breathing during sleep in patients affected by fibromyalgia syndrome. Eur Respir J. 1999; 14: 203-208.
19. Sarzi-Puttini P, Cazzola M, Randisi G, etal. Sleep alteration in fibromyalgia syndrome. J Func Syndromes. 2001; 2: 155-163.
20. Rizzi M, Sarzi-Puttini P, Atzeni F, et al. Cyclic Alternating Pattern: A new marker of sleep alteration in patients with fibromyalgia? J Rheumatol. 2004; 31: 1193-1199.
21. Benjamin S, Morris S, McBeth J. The association between chronic widespread pain and mental disorder: A population-based study. Arthritis Rheum. 2000; 43: 561-567.
22. Goldenberg DL. Fibromyalgia syndrome a decade later: What have we learned? Arch Intern Med. 1999; 159: 777-785.
23. Hawley DJ, Wolfe F. Depression is not more common in rheumatoid arthritis. a 10-year longitudinal study of 6,153 patients with rheumatic disease. J Rheumatol. 1993; 20: 2025-2031.
24. Wells KB, Golding JM, Burman MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry. 1988; 145: 976-981.
25. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995; 38: 19-28.
26. Neuman L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Report. 2003; 5: 887-888.
27. White KP, Speechley M, Hart M, Ostbye T. The London Fibromyalgia Epidemiology Study: The prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol. 1999; 26: 1570-1576.
28. Buskila D, Neuman L. Genetics of fibromyalgia. Curr Pain Headache Report. 2005; 9: 313-315.
29. Buskila D, Neuman L, Hazanov I, Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum. 1996; 26: 1-8.
30. Arnold LM, Hudson JI, Hess EV. Family study of fibromyalgia. Arthritis Rheum. 2004; 50: 944-952.
31. Hudson JI, Arnold LM, Keck PE Jr. Family study of fibromyalgia and affective spectrum disorder. Biol Psychiatry. 2004; 56: 884-891.
32. Offenbaecher M, Bondy B, de Jonge S. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulation region. Arthritis Rheum. 1999; 42: 2482-2488.
33. Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum. 2002; 46: 845-847.
34. Bondy B, Spaeth M, Offenbaecher M. The T102C polymorphism of the 5-HT2A- receptor gene in fibromyalgia. Neurobiol Dis. 1999; 6: 433-439.
35. Gursoy S, Erdal E, Herken H. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia. Rheumatol Int. 2003; 23: 104-107.
36. Wood PB. Stress and dopamine. implication for the pathophysiology of chronic widespread pain. Med Hypotheses. 2004; 62: 420-424.
37. Wood PB, Patterson JC, Sunderland JJ, Trainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: A pilot study. J Pain. 2007; 8: 51-58.
38. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic dysfunction in patients with fibromyalgia: Application of power spectral analysis of heart rate variability. Semin Arthritis Rheum. 2000; 29: 217-227.
39. Martinez-Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum. 2000; 29: 197-199.
40. Neumann L, Zeldets V, Bolotin A, Buskila D. Outcome of posttraumatic fibromyalgia. a 3-year follow-up of 78 cases of cervical spine injuries. Semin Arthritis Rheum. 2003; 32: 320-325.
41. Bartels EM, Danneskiold-Samsoe B. Histological abnormalities in muscle from patients with certain types of fibrositis. Lancet. 1988; 1: 755-757.
42. Bengtsson A, Henriksson K, Larsson J. Muscle biopsy in fibromyalgia: light microscopical and histochemical findings. Scand J Rheumatol. 1986; 15: 1-6.
43. McIver KL, Evans C, Kraus RM, Ispas L, Sciotti VM, Hickner RC. NO-mediated alteration in skeletal muscle nutritive blood flow and lactate metabolism in fibromyalgia. Pain. 2006; 120: 161-169.
44. Sarzi-Puttini P, Atzeni F, Montecucco M, et al. Surface EMG discloses central motor failure in patients with fibromyalgia syndrome. Ann Rheum Dis. 2005; abstract from Congress Proceeding of European League against Rheumatisms (EULAR).
45. Hakkinen A, Hakkinen K, Hannoneb P, Alen M. Force production capacity and acute neuromuscular responses to fatiguing loading in women with fibromyalgia are not different from those of healthy women. J Rheumatol. 2000; 27: 1277-1282.
46. Crofford LJ, Pillemer SR, Kalogeras KT. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994; 37: 1583-1592.
47. McCain GA, Tilbe KS. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol Suppl. 1989; 19: 154-157.
48. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol. 1993; 20: 469-474.
49. Weigent DA, Bradley LA, Blalock JE, Alarson GS. Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci. 1998; 315: 405-412.
50. Bennett RM. Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Report. 2002; 4: 306-312.
51. Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somatomedin C in patients with the fibromyalgia syndrome: A possible link between sleep and muscle pain. Arthritis Rheum. 1992; 35: 1113-1116.
52. Dinser R, Halama T, Hoffman A. Stringent endocrinological testing reveals subnormal growth hormone secretion in some patients with fibromyalgia syndrome but rarely severe growth hormone deficiency. J Rheumatol. 2000; 27: 2482-2488.
53. Wehrenberg WB, Janowski BA, Piering AW, Culler F, Jones KL. Glucocorticoids: Potent inhibitors and stimulators of growth hormone secretion. Endocrinology. 1990; 126: 3200-3203.
54. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998; 104: 227-231.
55. Mease P. Fibromyalgia syndrome. review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Supplement. 2005; 75: 6-21.
56. Russell IJ. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992; 35: 550-556.
57. Harris RE, Williams DA, McLean SA, et al. Characterization and consequences of pain variability in individuals with fibromyalgia. Arthr Rheum. 2005; 52: 3670-3674.
58. Levine JD, Reichling DB. Fibromyalgia: The nerve of that disease. J Rheumatol. 2005; 32(Suppl. 75): 29-37.
59. Lucas HJ, Brauch CM, Settas L, Theoharides TC. Fibromyalgia: New concepts of pathogenesis and treatment. Int J Imm Pharm. 2006; 19: 5-9.
60. Katz RS, Wolfe F, and Michaud K. Fibromyalgia diagnosis. A comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum. 2006; 54: 169-179.
61. Worrel LM, Krahn LE, Sletten CD. Treating fibromyalgia with a brief interdisciplinary program. initial outcomes and predictors of response. Mayo Clin Proc. 2001; 76: 384-390.
62. Burckhardt CS. Non-pharmacologic management strategies in fibromyalgia. Rheum Dis Clin North Am. 2002; 28: 291-304.
63. Burckhard CS. Multidisciplinary approaches for management of fibromyalgia. Curr Pharm Design. 2006; 12: 59-66.
64. Klug GA. Factors influencing the development and maintenance of aerobic fitness: Lessons applicable to the fibrositis syndrome. J Rheumatol Suppl. 1989; 19: 30-39.
65. Busch A, Schachter CL, Peloso PM, Bombardier C. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2002; 3: CD003786.
66. Mannerkorpi K. Exercise in fibromyalgia. Curr Opin Rheumatol. 2005; 17: 190-194.
67. Rooks DS, Silverman CB, Kantrowitz FG. The effects of progressive strength training and aerobic exercise on muscle strength and cardiovascular fitness in women with fibromyalgia: A pilot study. Arthritis Rheum. 2002; 47: 22-28.
68. Dobkin PL. Mainteinance of exercise in women with fibromyalgia. Arthr Rheum. 2005; 53: 724-731.
69. Lemstra M, Olszynski WP. The effectiveness of multidisciplinary rehabilitation in the treatment of fibromyalgia: A randomized controlled trial. Clin J Pain. 2005; 21: 166-174.
70. Gowans SE. Effect of a randomized, controlled trial of exercise on mood and physical function in individuals with fibromyalgia. Arthritis Rheum. 2001; 45: 519-529.
71. Moldofsky H. Sleep, neuroimmune, and neuroendocrine functions in fibromyalgia and chronic fatigue syndrome. Adv Neuroimmunol. 1995; 5: 39-56.
72. Godfrey RG. A guide to the understanding and use of tricyclic antidepressant in the overall management of fibromyalgia and other chronic pain syndromes. Arch Intern Med. 1996; 156: 1047-1052.
73. Carrette J, Bell MJ, Reynolds WJ, etal. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, placebo-controlled, double-blind, clinical trial. Arthritis Rheum. 1994; 37: 32-40.
74. Reynolds WJ, Moldofsky H, Saskin P, Lue FA. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol. 1991; 18: 452-454.
75. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004; 51: 9-13.
76. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002; 112: 191-197.
77. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996; 39: 1852-1859.
78. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003; 37: 1561-1565.
79. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003; 30: 1070-1074.
80. Littlejohn GO, Guymer EK. Fibromyalgia syndrome: Which antidepressant drug should we choose. Curr Pharmaceut Design. 2006; 12: 3-9.
81. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005; 32: 1975-1985.
82. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004; 19(Suppl. 1): S27-S35.
83. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo inthe treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004; 50: 2974-2984.
84. Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF. Duloxetine for the treatment of fibromyalgia in women: Pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt). 2007; 16: 1145-1156.
85. Freedenfeld RN, Murray M, Fuchs PN, Kiser RS. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Prac. 2006; 6: 112-118.
86. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005; 52: 2495-2505.
87. Russell IJ. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: A double-blind placebo-controlled study. Arthritis Rheum. 1991; 34: 552-560.
88. Crofford LJ, Rowbotham MC, Mease PJ, etal. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005; 52: 1264-1273.
89. Casale R. Buprenorfina transdermica nella fibromialgia. XXIX Congresso Nazionale AISD, Verona, 8-10. 2006, 6.
90. Staud R. Are tender point injections beneficial: The role of tonic nociception in fibromyalgia. Cur Pharm Des. 2006; 12: 23-27.